Synapse - Works

Results (5608)

TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician's choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Meeting Abstract

Ryan, C. J.; Abida, W.; Bryce, A. H.; Balar, A. V.; Dumbadze, I.; Given, R. W.; Morris, D.; Petrylak, D. P.; Redfern, C. H.; Scher, H. I.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study

Meeting Abstract

Sharma, P.; Callahan, M. K.; Bono, P.; Kim, J. W.; Spiliopoulou, P.; Calvo, E.; Pillai, R. N.; Ott, P. A.; De Braud, F. G.; Morse, M.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Winquist, E.; McLaughlin, B.; Lu, D.; Orr, S.; Fleisher, M.; Lowes, L.; Anderson, A. K. L.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma

Meeting Abstract

Pond, G. R.; Sonpavde, G.; Galsky, M. D.; Sharma, P.; Rosenberg, J. E.; Choueiri, T. K.; Bellmunt, J.; Lee, J. L.; Lee, S. I.; Azrilevich, A.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab

Meeting Abstract

Pond, G. R.; Niegisch, G.; Rosenberg, J. E.; Dreicer, R.; Powles, T.; Necchi, A.; Wei, X. X.; Grivas, P.; Balar, A. V.; Galsky, M. D.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

An open-label phase 1/2a study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rathkopf, D. E.; Saleh, M. N.; Tsai, F. Y. C.; Rosen, L. S.; Adams, B. J.; Liu, L.; Theuer, C. P.; Freddo, J. L.; Agarwal, N.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

EV-201 study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy

Meeting Abstract

Rosenberg, J. E.; Heath, E. I.; O'Donnell, P. H.; Hahn, N. M.; Balar, A. V.; Gartner, E. M.; Melhem-Bertrandt, A.; Petrylak, D. P.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study

Meeting Abstract

Petrylak, D. P.; Smith, D. C.; Flaig, T. W.; Zhang, J.; Sridhar, S. S.; Ruether, J. D.; Plimack, E. R.; Merchan, J. R.; Quinn, D. I.; Kilari, D.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study

Meeting Abstract

Necchi, A.; Pond, G. R.; Plimack, E. R.; Niegisch, G.; Yu, E. Y.; Pal, S. K.; Bamias, A.; Agarwal, N.; Alva, A. S.; Srinivas, S.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma

Meeting Abstract

Necchi, A.; Mariani, L.; Lo Vullo, S.; Raggi, D.; Giannatempo, P.; Bamias, A.; Crabb, S. J.; Bellmunt, J.; Yu, E. Y.; Niegisch, G.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save